In closed-loop broiler and layer barns where nipple drinker lines are chlorinated to 0.3–0.5 mg/L free chlorine and line pH drifts above 8.2 due to calcium bicarbonate scale, the oral-solution-grade API is metered through electric diaphragm proportioners at a 1:100 to 1:200 dilution ratio to produce a final drinking-water concentration of 0.05–0.15 mL/L, equivalent to 0.5–1.5 L API per 1,000 L medicated water. The addition ratio is not a fixed formulation constant: water consumption per kilogram of metabolic body weight varies with heat stress, and integrated poultry units using in-line conductivity probes commonly reset the proportioning rate within 1:128 to 1:256 to maintain the required intake. Regulatory compliance for this route follows the Chinese Veterinary Pharmacopoeia 2020 Qingwen Jiedu Oral Solution monograph and, for export formulation, EU Regulation 2019/6 Annex III provisions on oral solutions intended for drinking-water administration; microbiological attributes are verified by USP <61>/<62> with a total aerobic microbial count limit of 10² CFU/mL and absence of Escherichia coli per mL. Terminal product types are 500 mL and 1 L amber PET bottles with tamper-evident caps, plus 100 g and 1 kg foil-lined water-soluble powder sachets after spray-drying onto maltodextrin carrier. The downstream production process for the liquid form uses 316L jacketed mixing vessels at 25–28 °C, 0.45 µm polypropylene depth filtration to remove leaf and resin particulates, and rotary piston fillers under nitrogen blanketing; dissolved oxygen is held below 1.5 mg/L to protect polyphenolic marker compounds from oxidative darkening. In water-soluble powder production, the concentrate is spray-dried at inlet 165–175 °C and outlet 70–75 °C on a 35:65 w/w maltodextrin DE 10–15 carrier; subsequent V-blending with anhydrous citric acid adjusts reconstituted pH to 4.5–5.5. A production-scale failure mode observed in high-speed rotary piston filling is foam generation above 1,200 L/h when the concentrate is not vacuum-deaerated at 0.08 MPa, producing fill-volume variability of 2–3%. The formulation must not be mixed with free chlorine above 0.5 mg/L in the same stock tank because chlorination of the herbal aromatic system may reduce marker recovery after 60 min; published data for this specific configuration is limited, and operator validation against the approved summary of product characteristics is required.

What limits pellet die temperature when the extract is dry-loaded into swine feed granules?

Dry-loaded premix production differs from drinking-water medication because the API concentrate cannot be introduced directly into a horizontal ribbon mixer without prior adsorption onto a carrier. The current industrial practice begins with spray-drying the oral-solution-grade API at 30–40% w/w active solids on pregelatinised corn starch or silicon dioxide, yielding a free-flowing powder with moisture ≤5.0%. The powder is then preblended in a 500 kg ribbon mixer with a 1:15 dilution of corn starch to form a 5–7% w/w API premix. The premix is metered into complete swine feed at 2–5 kg per metric tonne, equivalent to 0.15–0.35 kg API solids per tonne, with the exact amount adjusted to the marker compound content stated in the Chinese Veterinary Pharmacopoeia 2020 monograph. Compliance for this route follows GB/T 16764-2006 for feed production hygiene, ISO 22000:2018 clause 8.5.3 for carry-over control, and Regulation (EC) No 183/2005 for feed hygiene where the API premix is produced for EU-recognised third-country export, with heavy metals screened by GB/T 13079-2006. The downstream process after preblending is conditioning at 70–75 °C for 40–50 s in a double-shaft steam conditioner, followed by ring-die pellet compression through a 3.0–3.5 mm die with a compression ratio of 1:8 to 1:10. Post-pelleting retention of marker compounds is the controlling process parameter: die temperature above 82 °C at the outer die surface reduces the concentration of thermally labile phenolic markers by 8–12% relative to pre-pelleting values, which is why several feed mills shift to post-pelleting liquid spray application of a 10% w/v API solution onto cooled pellets. Terminal product types are 5 kg and 25 kg multi-wall paper bags with PE inner liner for the premix, and 25 kg bags of nutritionally complete pelleted feed for nursery or grower-finisher pigs. An operational boundary observed at production scale is that carry-over of the premix into a following non-medicated batch may exceed 2.5 mg/kg if the micro-batching line lacks a dedicated 50 kg flush with ground corn; therefore, sequencing after a flush batch is mandatory under GB/T 16764-2006 hygiene plans. The dry-loaded premix should not be stored in unlined concrete silos above 65% RH, because the dried extract has a critical water activity near 0.60 and caking becomes irreversible within 24 h.

Because a sterile injectable grade of this herbal extract must meet the VICH sterility and endotoxin requirements before the API can be compounded into multi-dose vials, the preparation path begins with the oral-solution-grade liquid being clarified by tangential-flow filtration through a 0.65 µm polyethersulfone membrane, then aseptically mixed with Water for Injection at a ratio equivalent to 2.0–5.0% w/v dried extract. The addition ratio in injectable development is dictated not by feed intake but by the solubility of the ethanol-soluble fraction after solvent removal: formulations exceeding 50 mg/mL dried extract typically show visible precipitation when chilled to 4 °C, so the practical upper limit is set at 25–40 mg/mL marker-standardised extract. Regulatory compliance for the injectable route references VICH GL10 on impurities, VICH GL18 for residual solvent control, and USP General Chapters <71> for sterility, <85> for bacterial endotoxins with a limit of <0.5 EU/mg, and <788> for particulate matter. The downstream production process uses nitrogen-purged 316L stainless steel preparation vessels at 20–25 °C, addition of 0.05% w/v sodium metabisulfite as antioxidant, pH adjustment to 5.0–5.5 with dilute tromethamine or citric acid, and sterilising-grade filtration through a 0.22 µm PVDF cartridge. The filtered solution is filled in a restricted-access barrier isolator into 10 mL amber ampoules or 50 mL Type I glass vials under oxygen headspace below 1.0%; terminal steam sterilisation is avoided above 115 °C because the polyphenolic fraction undergoes pH-dependent oxidative degradation and marker compound recovery falls below 90% at 121 °C for 15 min in buffered bench models. Terminal product types are 10 mL single-dose ampoules, 20 mL and 50 mL multi-dose vials with antimicrobial preservative, and 100 mL infusion bottles for licensed veterinary use only. A production-scale failure pattern observed in aseptic filtration is a 30% decline in flux after 4,000 L/m² of filter area due to colloidal polyphenol–protein complexes that are not captured by the 0.65 µm clarification step; pre-filtration through a 0.45 µm diatomaceous earth depth pad extends the campaign. Published stability data for this specific extract in injectable configuration is limited; therefore, the above thresholds should be re-verified against the approved master file. The injectable formulation is incompatible with uncoated bromobutyl rubber closures containing high levels of leachable zinc compounds, which can chelate the flavonoid fraction and form visible cloudiness after 7 days of accelerated storage at 40 °C.

When a bovine bolus exceeds 4.5 g total weight, ejection shear and hygroscopic sticking become the controlling variables

Bolus manufacturing for adult ruminants imposes a compression window that is narrower than that of standard feed pellets because the lubricant levels needed to control ejection shear also reduce tensile strength. The dried API extract is wet-granulated with 20–35% w/w active solids, microcrystalline cellulose 30–40% w/w, dicalcium phosphate dihydrate 10–20% w/w, crospovidone 2–4% w/w, and magnesium stearate 0.5–0.8% w/w; the total blend moisture after tray drying is held to 2.5–3.5% rather than below 2.0%, because lower residual moisture causes lamination across the 12–18 kN main compression range. Addition ratio in the finished bolus is typically 0.5–1.5 g API dried solids per 4.5 g bolus for adult cattle, with smaller 0.8–1.5 g tablets used for calves. Compliance for this oral solid dosage route includes USP General Chapter <1217> for tablet breaking force, USP General Chapter <1216> for friability with a limit of ≤1.0%, VICH GL3 for stability testing, and ICH Q2(R2) for chromatographic method validation of marker compounds. The downstream production process uses a high-shear granulator with impeller speed 300–400 rpm and chopper speed 1,500–2,000 rpm, 40–45 °C fluid-bed drying to an air-inlet dew point below 10 °C, and a 16-station rotary tablet press with pre-compression at 8–10 kN and main compression at 16–22 kN. Ejection force above 12 kN on a 10.5 mm round die is the practical upper boundary; beyond this point, the ejection shear strips lubricant film and increases reject rate from 0.4% to 6% in unairconditioned compression rooms. Terminal product types are 2.5 g and 5.0 g bovine bolus tablets in thermoform blisters, plus 0.5 g calf tablets in polypropylene bottles with desiccant. Processing at relative humidity above 55% should be avoided unless the press is fitted with chilled punches and a segmented force feeder; the dried extract is hygroscopic and punch sticking becomes visible as a rising ejection-force trend within 45 min of continuous operation. The bolus matrix is incompatible with alkaline earth metal stearates above 1.0% w/w because magnesium stearate over-lubrication lowers radial tensile strength below 1.5 MPa, leading to capping in transit.

Companion animal capsule compounding and low-dose content uniformity limits

Companion-animal capsule compounding using the oral-solution-grade API requires an intermediate dried form, because direct liquid filling into hard gelatin capsules is precluded by the shell dissolution limit of water content above 20% w/w. The API is spray-dried onto microcrystalline cellulose or freeze-dried to a moisture content of ≤4.0%, then milled to a particle size with D90 below 150 µm to keep capsule weight variation below 3% at 50 mg fill weight. The addition ratio is adjusted to the target species and body weight: low-dose capsules are commonly compounded at 25–100 mg API dried solids per unit, blended with lactose monohydrate or dicalcium phosphate to a 1:4 to 1:10 total dilution. Regulatory compliance for this route is determined by the compounding jurisdiction: in the United States, animal-use compounding from bulk APIs falls under the FD&C Act Section 512(a)(4) and AMDUCA 21 CFR Part 530, while commercial contract manufacturing follows 21 CFR 211 or EU GMP Part I Chapter 3. Quality control uses USP <1174> for powder flow, USP <905> for content uniformity, and USP <711> for dissolution where a veterinary monograph exists. The downstream production process consists of low-shear tumble blending in a 100 L bin blender at 10–15 rpm for 20–30 min, then automatic capsule filling on a 1,500–3,000 capsule/h dosator machine with size 0 or size 1 HPMC or hard gelatin shells. Terminal product types are 30-count, 60-count, and 100-count HDPE bottles with induction-sealed child-resistant caps, plus unit-dose blister strips for veterinary clinics. A batch-to-batch variance issue observed during capsule production is that the dried extract’s flow character changes after milling: un-milled spray-dried product may have a Carr index above 30, causing dosator fill weight drift of ±8%, whereas a 0.5% w/w fumed silica addition reduces the Carr index to 18–20 but increases dissolution lag time by 10–15 min. The formulation should not be stored in uncoated blisters above 40 °C and 75% RH because the capsule fill cakes and marker compound recovery declines by 5–8% after 3 months under those conditions.